Johnson & Johnson delays roll-out to investigate ‘‘potentially deadly internal blood clots’’

- Advertisement -

Johnson & Johnson says it has decided to delay the roll-out of its coronavirus vaccine in Europe.
The decision follows a recommendation by US health authorities for a “pause” in administering the one-shot vaccine after reports that in a few very rare cases recipients developed blood clots.
Johnson & Johnson says it is reviewing the data with authorities in the United States and Europe, but that in the meantime it will “proactively delay the roll-out of our vaccine in Europe.”- The DPA reported

Last week, the European Medicines Agency announced it was investigating four reported incidents of potentially deadly internal blood clots following vaccination with Johnson & Johnson without changing its recommendation status.
Shortly before, EMA identified a similar possible link between clotting and British-Swedish drugmaker AstraZeneca’s shot in very rare cases, but upheld its backing for the jab. The benefits very much outweighed risks, according to the EU regulator.

- Advertisement -

Meanwhile, South Africa’s Health Minister Zweli Mkhize has announced the suspension of the Johnson & Johnson Covid-19 jab to investigate a possible link with blood clots.
Dr Mkhize said the decision was a “precautionary suspension.”

The US Food and Drug Administration (FDA) said six cases in 6.8 million doses had been reported and it was acting “out of an abundance of caution”.

- Advertisement -


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.